Combination therapy of metformin with anti-IGF1R mAb Figitumumab or an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor produces a synergistic effect in small cell lung cancer (SCLC) and NSCLC [2–4]. The gene discussed is IGF1R; the disease is small cell lung carcinoma.